Compass Therapeutics, Inc. — Income Charts
11 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$0
R&D↑+4.9% +$634K
$14M
D&A↓-87.9% -$123K
$17K
Operating Income↓-29.2% -$4M
$-16M
EBITDA↓-87.9% -$123K
$17K
Interest Expense
—
Interest Income↓-56.3% -$900K
$700K
Other Income/Expense↑+294.1% +$50K
$33K
Pretax Income↓-54.2% -$6M
$-17M
Tax Provision
$0
Net Income↓-36.0% -$4M
$-14M
Operating Margin
-1770.0%
Net Margin
-1538.4%
Effective Tax Rate↑+0.0pts
0.0%
DTA Valuation Allowance↑+33.2% +$20M
$79M
NOL Carryforwards
—
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-0.4pts
6.6%
ETR Foreign Differential (pp)↑+0.0pts
0.0%
Operating Lease Cost
—
Revenue YoY Variation
-100.0%
Income YoY Variation↓-26.6pts
-29.2%
Revenue QoQ Variation
-100.0%
Income QoQ Variation↑+6.3pts
24.9%